Please assess the completion status of the following clinical trial:

Trial Title: HEMOBLAST Pivotal Clinical Investigation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* • Subject is undergoing an elective open cardiothoracic, abdominal, or orthopedic lower extremity surgery;~  * Subject or an authorized legal representative is willing and able to give prior written informed consent for investigation participation;~ * Subject undergoing cardiothoracic surgery is not allergic to protamine; and~ * Subject is 21 years of age or older.~Exclusion Criteria:~* • Subject is undergoing a laparoscopic, thoracoscopic, or robotic surgical procedure;~  * Subject is undergoing a neurologic surgical procedure;~ * Subject is undergoing a spinal surgical procedure;~ * Subject is undergoing an emergency surgical procedure;~ * Subject is pregnant, planning on becoming pregnant during the follow-up period, or actively breast-feeding;~ * Subject has a clinically significant coagulation disorder or disease, defined as a platelet count \< 100,000 per microliter or International Normalized Ratio \> 1.5 within 4 weeks of surgery;~ * Subject receiving intravenous heparin within 12 hours before surgery or oral Coumadin within 2 days before surgery;~ * Subject receiving antiplatelet medications within 5 days prior to surgery;~ * Subject undergoing abdominal or orthopedic lower extremity surgery receiving aspirin within 7 days prior to surgery;~ * Subject has an active or suspected infection at the surgical site;~ * Subject has had or has planned to receive any organ transplantation;~ * Subject has a known sensitivity or allergy to bovine and/or porcine substance(s) or any other component(s) of the hemostatic agent;~ * Subject has ASA classification of 5;~ * Subject has a life expectancy of less than 3 months;~ * Subject has a known psychiatric disorder, which in the opinion of the Principal Investigator, would preclude the subject from completing this clinical study;~ * Subject has a documented severe congenital or acquired immunodeficiency;~ * Subject has religious or other objections to porcine, bovine, or human components;~ * Subject in whom the investigational or control device will be used at the site of a valve replacement or repair;~ * Subject in whom the investigational or control device will be used at the site of a synthetic graft or patch implant;~ * Subject is currently participating or has participated in another clinical trial within the past 30 days and is receiving/has received an investigational drug, device, or biologic agent; and~ * Subject is not appropriate for inclusion in the clinical trial, per the medical opinion of the Principal Investigator.~Intraoperative Eligibility Criteria:~* Subject does not have an active or suspected infection at the surgical site;~* Subject undergoing cardiothoracic surgery with anticoagulation must have anticoagulation reversed prior to target bleeding site (TBS) identification and treatment;~* Subject in whom the Investigator is able to identify a TBS for which any applicable conventional means for hemostasis are ineffective or impractical; and~* Subject has a TBS with an SBSS score of 1, 2, or 3.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Investigational (Type: EXPERIMENTAL): HEMOBLAST Bellows
- Control (Type: ACTIVE_COMPARATOR): Absorbable gelatin sponge, USP with thrombin

Based on this trial design, predict the completion outcome and termination type (if applicable).